Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study

被引:20
|
作者
Kim, Se Hwa [1 ]
Lee, Young-Kyun [2 ]
Kim, Tae-Young [3 ]
Ha, Yong-Chan [4 ]
Jang, Sunmee [5 ,6 ]
Kim, Ha Young [7 ,8 ]
机构
[1] Catholic Kwandong Univ, Int St Marys Hosp, Dept Internal Med, Coll Med, Incheon, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Orthopaed Surg, Seongnam, South Korea
[3] Konkuk Univ, Sch Med, Dept Orthopaed Surg, Seoul, South Korea
[4] Chung Ang Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea
[5] Gachon Univ, Coll Pharm, Incheon, South Korea
[6] Gachon Univ, Gachon Inst Pharmaceut Sci, Incheon, South Korea
[7] Wonkwang Univ, Sanbon Hosp, Dept Internal Med, Coll Med, Gunpo, South Korea
[8] Univ Ulsan, Gangneung Asan Hosp, Dept Internal Med, Coll Med, Kangnung, South Korea
关键词
Bisphosphonates; Osteonecrosis of the jaw; Osteoporosis; Periodontal disease; SUPPRESSED BONE TURNOVER; ZOLEDRONIC ACID; POSTMENOPAUSAL OSTEOPOROSIS; RHEUMATOID-ARTHRITIS; ALENDRONATE; FRACTURES; WOMEN; ASSOCIATION; PREVALENCE;
D O I
10.1016/j.bone.2020.115650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To estimate the incidence of osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs) and to identify clinical risk factors that increase the risk for ONJ in Korean osteoporosis patients. Methods: We used data acquired from the Korean National Health Insurance Service. Among 2,140,149 participants with osteoporosis in 2012, we selected 164,926 new BP users and 164,926 ageand sex-matched control subjects. The control group included only patients with no prescriptions for BPs between January 1, 2011, and December 31, 2016. Participants were followed for 4 years. Results: Over the 4-year follow-up period, the cumulative incidence rates of ONJ were 20.9 and 6.9 per 100,000 person-years in the BP and control groups, respectively. The BP group had an increased risk for ONJ compared to the control group after adjusting for multiple variables (hazard ratio [HR] 3.72, 95% CI 2.70-5.11). Advanced age (>= 70 years), comorbid diseases such as diabetes, hypertension, and rheumatoid arthritis (RA) were independent risk factors for the development of ONJ. In addition, tooth extraction (HR 9.85), gingivitis, and periodontal disease (HR 4.78) were strongly associated with ONJ. Conclusions: ONJ incidence was 21 per 100,000 person-years in osteoporosis patients receiving bisphosphonates. Clinical factors including advanced age, diabetes, RA, dental disease, as well as BP use were significantly associated with ONJ.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden
    Hallmer, Fredrik
    Bjornland, Tore
    Nicklasson, Anders
    Becktor, Jonas P.
    Andersson, Gunilla
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2014, 118 (02): : 202 - 208
  • [32] Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer
    Goodwin, James S.
    Zhou, Jie
    Kuo, Yong-Fang
    Baillargeon, Jacques
    MAYO CLINIC PROCEEDINGS, 2017, 92 (01) : 106 - 113
  • [33] Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates
    Gebara, Shereen Nabhani
    Moubayed, Hiba
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (17) : 1541 - 1547
  • [34] Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan
    Ishimaru, Miho
    Ono, Sachiko
    Morita, Kojiro
    Matsui, Hiroki
    Hagiwara, Yasuhiro
    Yasunaga, Hideo
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2022, 80 (04) : 714 - 727
  • [35] A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study
    Kwon, J. -W.
    Park, E. -J.
    Jung, S. -Y.
    Sohn, H. S.
    Ryu, H.
    Suh, H. S.
    JOURNAL OF DENTAL RESEARCH, 2015, 94 (09) : 212S - 219S
  • [36] Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid
    Taguchi, Akira
    Uemura, Yukari
    Imai, Takumi
    Tanaka, Shiro
    Ohta, Hiroaki
    Nakamura, Toshitaka
    Orimo, Hajime
    Sugimoto, Toshitsugu
    Soen, Satoshi
    Shiraki, Masataka
    JOURNAL OF BONE AND MINERAL METABOLISM, 2019, 37 (05) : 886 - 892
  • [37] Osteonecrosis of The Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated With Bisphosphonates With/Without Bevacizumab
    Ngamphaiboon, Nuttapong
    Frustino, Jennifer L.
    Kossoff, Ellen B.
    Sullivan, Maureen A.
    O'Connor, Tracey L.
    CLINICAL BREAST CANCER, 2011, 11 (04) : 252 - 257
  • [38] Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis
    Zhang, Chengrong
    Shen, Guoshuang
    Li, Huihui
    Xin, Yuanfang
    Shi, Mingqiang
    Zheng, Yonghui
    Wang, Miaozhou
    Liu, Zhen
    Zhao, Yi
    Zhao, Fuxing
    Ren, Dengfeng
    Zhao, Jiuda
    SPECIAL CARE IN DENTISTRY, 2024, 44 (02) : 530 - 541
  • [39] A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates
    Thumbigere-Math, Vivek
    Tu, Lam
    Huckabay, Sabrina
    Dudek, Arkadiusz Z.
    Lunos, Scott
    Basi, David L.
    Hughes, Pamela J.
    Leach, Joseph W.
    Swenson, Karen K.
    Gopalakrishnan, Rajaram
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (04): : 386 - 392
  • [40] BISPHOSPHONATES RELATED OSTEONECROSIS OF THE JAW IN CANCER PATIENTS-EPIDEMIOLOGICAL STUDY
    Ciobanu, George Adrian
    Camen, Adrian
    Ionescu, Mihaela
    Vlad, Daniel
    Mercut, Veronica
    Staicu, Ionela Elisabeta
    Petrescu, Gabriel Sebastian
    Asan, Adel Aila
    Popescu, Sanda Mihaela
    ROMANIAN JOURNAL OF ORAL REHABILITATION, 2022, 14 (03): : 56 - 66